WST

AIEQ has been accumulating West almost daily from 2026-10-14 to 2026-10-23, lifting its weight from 1.40% to 1.52%, while LQAI and QRFT hold only token positions. That buying conflicts with a Buffett-style read, which respects the business and its moat but fails it on margin of safety at roughly 49 times earnings. The AIs appear to be backing momentum and quality, whereas the framework would want a much lower price.

• Circle of CompetenceWest makes elastomer stoppers, seals and injection components for injectable drugs, a steady, recurring, regulation-driven consumables business whose unit economics are predictable enough to project ten-year cash flows.
• Economic MoatIts components are specified into regulated drug filings, so switching costs are high, and its scale and long-standing quality record in a narrow niche give it a durable moat.
• ManagementCandor and capital allocation cannot be judged from the supplied data, and no insider ownership, buyback or acquisition history is provided.
• Financial HealthAn ROE of 18.51% and 12.38% revenue growth point to strong returns on capital, though the data does not show the ten-year ROE floor, margin trend, debt load or owner earnings, so this pass is provisional.
• Margin of SafetyA P/E of 48.84, price-to-book of 6.23 and EV/EBITDA of 62.62 price in years of flawless growth, which leaves no margin of safety against a conservative estimate of intrinsic value.

West is a predictable, moat-protected business with solid returns on equity, so it clears the circle of competence and moat tests, but management could not be judged from the data. The valuation is the problem: at these multiples there is no margin of safety, so the framework returns a Fail on price rather than on business quality.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.